We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
Baldwin, D. S.et al. (2013). Benzodiazepines: risks and benefits. A reconsideration. Journal of Psychopharmacology, 27, 967–971.CrossRefGoogle ScholarPubMed
Baldwin, D. S.et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28, 403–439.CrossRefGoogle ScholarPubMed
Bergman, H., Bhoopathi, P. S. and Soares-Weiser, K. (2018). Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews, 1, CD000205. doi: 10.1002/14651858.CD000205.pub3.Google ScholarPubMed
Bertz, R. J.et al. (1997). Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. Journal of Pharmacology and Experimental Therapeutics, 281, 1317–1329.Google Scholar
Bohlken, J. and Kostev, K. (2018). Prevalence and risk factors for delirium diagnosis in patients followed in general practices in Germany. International Psychogeriatrics, 30, 511–518.CrossRefGoogle ScholarPubMed
Brimelow, R. E., Wollin, J. A., Byrne, G. J., Dissanayaka, N. N. (2018). Prescribing of psychotropic drugs and indicators for use in residential aged care and residents with dementia. International Psychogeriatrics, 31,
837–847.CrossRefGoogle ScholarPubMed
Chung, J. K.et al. (2016). Benzodiazepine use attenuates cortical β-amyloid and is not associated with progressive cognitive decline in nondemented elderly adults: a Pilot Study using F18-Florbetapir positron emission tomography. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 24, 1028–1039.CrossRefGoogle Scholar
Crowe, S. F. and Stranks, E. K. (2018). The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Archives of Clinical Neuropsychology, 33, 901–911.CrossRefGoogle ScholarPubMed
Cumming, R. G. and Le Couteur, D. G. (2003). Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs, 17,
825–837.CrossRefGoogle Scholar
Davies, S. J. C., Jacob, B., Rudoler, D., Zaheer, J., de Oliveira, C. and Kurdyak, P. (2018). Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013. Therapeutic Advances in Psychopharmacology, 8, 99–114.CrossRefGoogle ScholarPubMed
Gray, S. L.et al. (2016). Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ, 352, i90.Google ScholarPubMed
Horiguchi, J., Nishimatsu, O. and Inami, Y. (1989). Successful treatment with clonazepam for neuroleptic-induced akathisia. Acta Psychiatrica Scandinavica, 80,
106–107.CrossRefGoogle ScholarPubMed
Howanitz, E.et al. (1999). The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. The Journal of Clinical Psychiatry, 60, 41–44.CrossRefGoogle ScholarPubMed
Jeste, D. V., Barak, Y., Madhusoodanan, S., Grossman, F. and Gharabawi, G. (2003). International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. The American Journal of Geriatric Psychiatry, 11, 638–647.CrossRefGoogle ScholarPubMed
Kahn, J. P., Puertollano, M. A., Schane, M. D. and Klein, D. F. (1988). Adjunctive alprazolam for schizophrenia with panic anxiety: clinical observation and pathogenetic implications. The American Journal of Psychiatry, 145, 742–744.Google ScholarPubMed
Katzman, M. A.et al. (2014). Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry, 14, S1.CrossRefGoogle ScholarPubMed
Lewis, D. A., Hashimoto, T. and Volk, D. W. (2005). Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience6, 312–324.CrossRefGoogle Scholar
Machado-Duque, M. E., Castaño-Montoya, J. P., Medina-Morales, D. A., Castro-Rodríguez, A., González-Montoya, A. and Machado-Alba, J. E. (2018). Association between the use of benzodiazepines and opioids with the risk of falls and hip fractures in older adults. International Psychogeriatrics, 30,
941–946.CrossRefGoogle ScholarPubMed
Möhler, H. (2006). GABAA receptor diversity and pharmacology. Cell and Tissue Research, 326,
505–516.CrossRefGoogle Scholar
Sampson, S. J.et al. (2017). Benzodiazepines for psychosis–induced aggression or agitation. Cochrane Database of Systematic Reviews, CD003079. Published online 2017 Dec 8. doi: 10.1002/14651858.CD003079.pub4.CrossRefGoogle Scholar
Schuster, J. P.et al. (2019). Benzodiazepine use among older adults with schizophrenia spectrum disorder. International Psychogeriatrics, 32, 441–451. doi: 10.1017/S1041610219000358.CrossRefGoogle ScholarPubMed
Sim, F., Sweetman, I., Kapur, S. and Patel, M. X. (2015). Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. Journal of Psychopharmacology, 29, 212–223.CrossRefGoogle ScholarPubMed
Thomas, R. E. (1998). Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Canadian Family Physician, 44, 799–808.Google ScholarPubMed
Tzimos, A.et al. (2008). Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. The American Journal of Geriatric Psychiatry, 16, 31–43.CrossRefGoogle ScholarPubMed